Cargando…

The Increased Ischemic Risk During the Early Period After Clopidogrel Noncompliance in Patients with Acute Coronary Syndrome: A Meta-Analysis

Although dual antiplatelet therapy for secondary prevention in acute coronary syndrome (ACS) is highly recommended by current guidelines, P2Y(12) inhibitor non-adherence often occurs and devastates prognosis. To evaluate whether the ischemic risk during the early period of clopidogrel noncompliance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yushan, Zhao, Ruting, Yu, Peng, Xu, Yan, Zhang, Quanyu, Han, Yaling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469223/ https://www.ncbi.nlm.nih.gov/pubmed/37644847 http://dx.doi.org/10.1177/10760296231196477

Ejemplares similares

Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
por: He, Peixun, et al.
Publicado: (2021)

De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis
por: Angiolillo, Dominick J., et al.
Publicado: (2019)

Determinants to optimize response to clopidogrel in acute coronary syndrome
por: Giusti, Betti, et al.
Publicado: (2010)

The Noncompliant Patient
por: Young, James B., et al.
Publicado: (2022)

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
por: Wang, Dong, et al.
Publicado: (2018)

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis
por: Chenna, Venkata Sai Harshabhargav, et al.
Publicado: (2023)

Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke
por: Yi, Xingyang, et al.
Publicado: (2018)

Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel
por: Yi, Xingyang, et al.
Publicado: (2020)

The Unhidden Cost of Noncompliance
por: Mahoney, John J., et al.
Publicado: (2008)

Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low‐Dose Prasugrel or Clopidogrel
por: Crimi, Gabriele, et al.
Publicado: (2019)

Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome
por: Moon, Hyeyeon, et al.
Publicado: (2021)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis
por: Sun, Mengyi, et al.
Publicado: (2022)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
por: Fan, Zhong-Guo, et al.
Publicado: (2019)

Informative noncompliance in endpoint trials
por: Snapinn, Steven M, et al.
Publicado: (2004)

Treatment compliance and noncompliance in psychoses
por: Rao, K. Nagaraja, et al.
Publicado: (2017)

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada
por: Grima, Daniel T, et al.
Publicado: (2014)

Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome
por: Liu, Lin, et al.
Publicado: (2018)

2220: Pharmacogenomic determinants in Caribbean Hispanics of clopidogrel failure in acute coronary syndrome
por: Melin, Kyle, et al.
Publicado: (2018)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023)

De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early?
por: Masiero, Giulia, et al.
Publicado: (2020)

Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment
por: Shoji, Satoshi, et al.
Publicado: (2020)

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
por: Li, Yi, et al.
Publicado: (2020)

Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention After Risk Stratification With the CHA(2)DS(2)-VASc Score
por: Na, Kun, et al.
Publicado: (2022)

Delayed Management of Zollinger-Ellison Syndrome in a Noncompliant Patient
por: Klimko, Artsiom, et al.
Publicado: (2020)

Postoperative Noncompliance following Repair of Acute Achilles Tendon Ruptures
por: Rogero, Ryan G., et al.
Publicado: (2020)

Clinical, Pharmacokinetic, and Pharmacogenetic Determinants of Clopidogrel Resistance in Korean Patients with Acute Coronary Syndrome
por: Park, Kyoung-Jin, et al.
Publicado: (2011)

Quality of life (QOL) evaluation after acute coronary syndrome with simultaneous clopidogrel treatment
por: Chudek, Jerzy, et al.
Publicado: (2013)

Inflammatory and Antioxidant Pattern Unbalance in “Clopidogrel-Resistant” Patients during Acute Coronary Syndrome
por: Caruso, Raffaele, et al.
Publicado: (2015)

Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome: Erratum
Publicado: (2018)

Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel
por: ALGÜL, Engin, et al.
Publicado: (2019)

Ticagrelor Versus Clopidogrel in East Asian Patients With Acute Coronary Syndrome and Diabetes Mellitus
por: Choi, Yeonwoo, et al.
Publicado: (2022)

Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
por: Su, Qiang, et al.
Publicado: (2019)

Noncompliance to DOTS: How it can be Decreased
por: Mittal, Chhaya, et al.
Publicado: (2011)

Not Getting to Goal: The Clinical Costs of Noncompliance
por: Ansell, Benjamin J.
Publicado: (2008)

Platelet reactivity after clopidogrel loading in patients with acute ischemic stroke
por: Enomoto, Yukiko, et al.
Publicado: (2022)

Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study
por: Yao, Ying, et al.
Publicado: (2019)

Severe Rhabdomyolysis and Acute Renal Failure Due to Noncompliance to Levothyroxine Therapy
por: Raj, Rishi, et al.
Publicado: (2021)

Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
por: Zhao, Xiangkai, et al.
Publicado: (2021)

Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap
por: Page, Robert Lee, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_f61kej28iikf0sk69jq85om3bl